Article
Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology - 1 Jul 2002
Lerer Bernard, Segman Ronnen H, Fangerau Heiner, Daly Ann K, Basile Vincenzo S, Cavallaro Roberto, Aschauer Harald N, McCreadie Robin G, Ohlraun Stephanie, Ferrier Nicol, Masellis Mario, Verga Massimiliano, Scharfetter Joachim, Rietschel Marcella, Lovlie Roger, Levy Uriel Heresco, Meltzer Herbert Y, Kennedy James L, Steen Vidar M, Macciardi Fabio
Abstract excerpt
Variability among individuals in their therapeutic response to psychotropic drugs and in susceptibility to adverse effects is considerable. Pharmacogenetics addresses the contribution of genetic factors to this variability. An important focus of interest in pharmacogenetics has been on candidate genes that play a role in susceptibility to the antipsychotic drug-induced adverse effect, tardive dyskinesia (TD)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.